Skip to content

Efficacy Evaluation of Runmu Granules in the Treatment of Dry Eye of Qi-Yin Deficiency Type

Efficacy Evaluation of Runmu Granules in the Treatment of Dry Eye of Qi-Yin Deficiency Type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001200
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye disease

Interventions

Group of Runmu Granules + Placebo Eye Drops:Runmu Granules shall be dissolved in boiling water for oral administration twice daily, combined with Polyvinyl Alcohol Eye Drops instilled 1-2 drops each t
Placebo + Polyvinyl Alcohol Eye Drops Group:The placebo shall be dissolved in boiling water for oral administration twice daily, combined with Polyvinyl Alcohol Eye Drops instilled 1-2 drops per time,

Sponsors

China Academy of Chinese Medical Sciences Ophthalmic Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with aqueous-deficient dry eye meeting the Western medical diagnostic criteria;(2) TCM syndrome differentiation consistent with qi-yin deficiency type;(3) Aged 35-70 years old;(4) Patients who have signed the informed consent form and voluntarily participated in this clinical study.

Exclusion criteria

Exclusion criteria: (1) Patients with ocular surface diseases that affect observation and efficacy evaluation, such as keratitis, corneal ulcer, iridocyclitis, and pterygium;(2) Patients with diseases that significantly affect physical status, such as tumors and liver cirrhosis;(3) Patients with systemic autoimmune diseases, such as Sjögren's syndrome;(4) Patients scheduled for surgery during the trial period;(5) Patients participating in other research trials simultaneously during the treatment and observation period;(6) Patients using drugs that interfere with efficacy during the medication period, such as anticholinergic drugs and corticosteroids;(7) Pregnant or lactating women, and patients with allergies;(8) Patients with poor compliance who cannot cooperate with treatment and observation.

Design outcomes

Primary

MeasureTime frame
fluorescein breakup time,FBUT;Tear Secretion Test (Schirmer I Test);Reduce the frequency of artificial tear instillation.;

Secondary

MeasureTime frame
Measurement of tear meniscus height (TMH);(corneal fluorescein staining,CFS);Meibomian Gland Function Assessment;Dry Eye Symptom Score;TCM syndrome score;Serum lipid metabolism;

Countries

China

Contacts

Public ContactYan jing

China Academy of Chinese Medical Sciences Ophthalmic Hospital

yifly8377@sina.com13611177527

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026